Printer Friendly

ADVANCED TISSUE SCIENCES PRESENTS DATA ON VARIETY OF TISSUES FOR TRANSPLANTATION

 ADVANCED TISSUE SCIENCES PRESENTS DATA ON
 VARIETY OF TISSUES FOR TRANSPLANTATION
 LA JOLLA, Calif., April 8 /PRNewswire/ -- Researchers from Advanced Tissue Sciences Inc. (NASDAQ-NMS: ATISA) are presenting data on the growth of cartilage, liver, skin and bone marrow using the company's proprietary tissue engineering technology. The data are being presented at the Keystone Tissue Engineering Conference (Keystone, Colo.) and the Federation of the American Society of Experimental Biology Conference (FASEB Anaheim, Calif.)
 "These presentations document our ability to successfully replicate a variety of tissues in vitro (outside the body)," said Gail K. Naughton, Ph.D., Advanced Tissue Sciences' executive vice president and chief operating officer. "The primary goal of our tissue engineering research is to grow these tissues as replacements for damaged or failing organs. The benefits of this research could positively impact the lives of patients requiring organ transplants as well as those who suffer from diseases or injuries of their joints."
 A presentation on cartilage reported use of the company's proprietary three-dimensional culture system to successfully grow human chondrocytes, or cartilage cells, into functional cartilage tissue in vitro. An engineered physiologic cartilage has important implications in corrective surgery and in the treatment of diseased or injured articular surfaces of joints.
 The company is also presenting data which indicate that their three- dimensional culture systems supports the long-term growth of liver tissue which retains the ability to metabolize drugs. Tissues derived from these cultures may be useful in liver transplantation and gene therapy.
 The availability of engineered tissues would substantially improve the prognosis for many patients. Engineered liver tissue could potentially be used to treat cirrhosis and in-born defects in liver, ailments which affect more than 150,000 people in the United States each year. Engineered cartilage tissue could be used to treat the greater than 800,000 individuals in the United States suffering from injuries or diseases of the joint.
 Last week, Advanced Tissue Sciences announced signing a letter of intent to acquire Neomorphics Inc., a research and development company focused on the engineering of human tissue and organ replacements. The proposed acquisition is scheduled to close in mid-August 1992, subject to satisfactory completion of various contingencies. Neomorphics' sponsored research at the Children's Hospital, an affiliate of Harvard Medical School, and M.I.T. has demonstrated the utility of engineered cartilage and liver tissues in animal models. The synergy of the two companies is expected to accelerate the introduction of Advanced Tissue Sciences' next therapeutic products based on liver and cartilage tissues.
 In several other scientific presentations company scientists are presenting progress on research involving skin, bone marrow and genetically engineered tissues. At the American Burn Association meeting (Salt Lake City) researchers reported that the clinical trial of Dermagraft (TM), its living human dermal replacement for treating burns, has been conducted on greater than 75 patients and has continued to show promise for the treatment of severe burn wounds. In separate presentations at the Keystone and FASEB conferences the company's results demonstrated that its core technology supports the long-term proliferation of marrow stem-cells and serves as an effective delivery vehicle for genetically engineered fibroblasts (skin cells).
 "As genetic engineering profoundly impacted the 1980s, we believe tissue engineering will come of age in the 1990s," Naughton added. "Our proposed acquisition of Neomorphics will further solidify our leadership position in this new field."
 Advanced Tissue Sciences (formerly Marrow-Tech Inc.) is a tissue engineering company engaged in the growth of human tissues and organs for potential therapeutic and laboratory applications. The company's core technology enables living human cells to develop and assemble into functional three-dimensional tissues in culture. Using this technology, the company has successfully replicated a variety of human tissues, including skin, cartilage, oral mucosa, bone marrow and liver. The company is currently marketing its Skin2(TM) toxicology testing products domestically and internationally, and is conducting multi-center clinical trials of Dermagraft, its living dermal replacement product, in burn and wound care centers in the United States.
 -0- 4/8/92
 /CONTACT: James P. Linton, Ph.D., of Advanced Tissue Sciences, 619-450-5707/
 (ATISA) CO: Advanced Tissue Sciences ST: California IN: MTC SU:


AL-CH -- SD005 -- 6215 04/08/92 11:33 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 8, 1992
Words:690
Previous Article:ATHLONE DECLARES DIVIDEND
Next Article:OLDSMOBILE INTRODUCES 'GREAT NINETY EIGHT SMARTLEASE'


Related Articles
ADVANCED TISSUE SCIENCES ANNOUNCES LETTER OF INTENT TO ACQUIRE NEOMORPHICS INC.
ADVANCED TISSUE SCIENCES AND NEOMORPHICS SIGN DEFINITIVE ACQUISITION AGREEMENT
ADVANCED TISSUE SCIENCES PRESENTS CARDIOVASCULAR DATA AT AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS
ADVANCED TISSUE SCIENCES ANNOUNCES STATISTICALLY SIGNIFICANT RESULTS FROM DERMAGRAFT-TC PIVOTAL CLINICAL TRIAL AND INTENTION TO SUBMIT PMA
Advanced Tissue Sciences - Dermagraft Clinical Performance
Advanced Tissue Sciences Submits Investigational Device Exemption Application For Tissue Engineered Human Articular Knee Cartilage
FDA Accepts Dermagraft(R) PMA Application for Filing
Advanced Tissue Sciences, MIT and Children's Hospital, Boston Announce New Tissue Engineering Patents
Advanced Tissue Sciences, MIT and Children's Hospital of Boston announce new tissue engineering patents
Advanced Tissue Sciences Presents Data on Vascular Endothelialization Growth Factor (VEGF) Secretion.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters